机构:[1]Institute of Tissue Engineering and Stem Cells, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, P. R. China[2]Department of Biology, North Sichuan Medical College, Nanchong, Sichuan, P.R. China[3]Department of Oncology, the Fifth People’s Hospital of Chengdu, The Second Clinical Medical School of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China[4]Sichuan Chidingshengtong Biotechnology Co., Ltd., Chengdu, Sichuan, P.R. China[5]Precision Medicine Center, Nanchong Central Hospital, Nanchong, Sichuan, P.R. China
Objective: It has been reported that 80% of all breast carcinoma cases are invasive ductal
carcinoma (IDC), and 45% to 78% of invasive breast carcinoma cases are associated with
ductal carcinoma in situ (DCIS). Therefore, it is important to gain insights into transcriptome
changes that occur during DCIS progression to IDC.
Methods: We downloaded Gene Expression Omnibus databases GSE21422 and GSE3893, and
performed differentially expressed gene (DEG) analysis and cluster analysis, followed by pathway
enrichment analysis and Oncomine analysis.
Results: Twenty-six conserved DEGs were identified in both GSE21422 and GSE3893. These
genes are mainly enriched in intermediate filament-based processes, immune responses,
Staphylococcus aureus infection response, and phagosomes. Among them, FCGR2A, HLA-DRA,
C3AR1, and FYB were reported to be involved in DCIS progression to IDC. High expression
of HLA-DRA, C3AR1, and FYB in different types of breast cancer was validated using different
Oncomine datasets. Moreover, elevated HLA-DRA and FYB levels were associated with breast cancer recurrence. Importantly, the overexpression of FYB was correlated with breast
cancer metastasis.
Conclusions: This study revealed the molecular characteristics associated with progression
from DCIS to IDC. It also identified potential biomarkers for DCIS progression to IDC, which
will aid breast cancer diagnosis and prevention.
基金:
The study was supported by the Educational
Department of Sichuan Province Research
Projects (grant numbers 17ZA0175, 17ZA0176,
and 16ZA0242) and Nanchong Science and
Technology Bureau Research Projects (grant
numbers NSMC20170460, NSMC20170410,
and 15A0035).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区药学
最新[2023]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区药学
第一作者:
第一作者机构:[1]Institute of Tissue Engineering and Stem Cells, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, P. R. China[2]Department of Biology, North Sichuan Medical College, Nanchong, Sichuan, P.R. China
通讯作者:
通讯机构:[1]Institute of Tissue Engineering and Stem Cells, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, P. R. China[5]Precision Medicine Center, Nanchong Central Hospital, Nanchong, Sichuan, P.R. China[*1]97 South Renmin Road, Nanchong, Sichuan 637000, P.R. China.
推荐引用方式(GB/T 7714):
Guiqin Song,Lang He,Xiaolin Yang,et al.Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma.[J].The Journal of international medical research.2020,48(1):300060518815364.doi:10.1177/0300060518815364.
APA:
Guiqin Song,Lang He,Xiaolin Yang,Yan Yang,Xiaoming Cai...&Gang Feng.(2020).Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma..The Journal of international medical research,48,(1)
MLA:
Guiqin Song,et al."Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma.".The Journal of international medical research 48..1(2020):300060518815364